Lexicon Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael S. Exton
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2445 Technology Forest Boulevard The Woodlands TX United States of America 77381
- IPO Date
- Apr 7, 2000
- CIK
- 0001062822
- Website
- lexpharma.com
- Similar Companies
- Business
- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a biopharmaceutical company focused on discovering and developing treatments for diabetes, metabolic disorders, and other chronic diseases through its proprietary gene knockout technology. The company offers a pipeline of investigational drug candidates, including sotagliflozin (brand name Inpefa), an SGLT1 and SGLT2 dual inhibitor approved for heart failure and chronic kidney disease in type 2 diabetes patients; LX9211, a central nervous system-penetrant EP2 receptor antagonist in Phase 2 trials for neuroinflammation-related conditions; LX9851, a peripherally restricted EP2 antagonist for peripheral inflammatory diseases; and earlier-stage programs targeting neuropathic pain, obesity, and hypoparathyroidism. Founded in 1994 and headquartered in The Woodlands, Texas, Lexicon operates primarily in the United States with clinical trials conducted globally. Recent developments include positive Phase 3 trial results for Inpefa in expanding indications announced in late 2024, a strategic licensing partnership with Novo Nordisk for LX9211 development in 2025, and a $100 million financing round closed in Q3 2025 to support pipeline advancement and manufacturing scale-up.
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average – Here’s Why
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Lexicon Pharmaceuticals Q4 Earnings Call Highlights
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences